Deoxyribonuclease (DNase I, EC 3.1.21.1) is an endonuclease that catalyzes the hydrolytic cleavage of phosphodiester linkages in DNA, preferentially adjacent to pyrimidine nucleotides, degrading both double-stranded and single-stranded DNA to oligonucleotide-sized products or shorter. DNase I has historically been purified from bovine pancreas, a tissue that is one of the richest sources of RNase activity, containing approximately 1 mg of RNase A per gram of tissue. This animal-derived origin introduces risks of viral and prion contamination, batch-to-batch variability, and significant RNase contamination that can compromise RNA integrity in sensitive molecular biology workflows.

Animal-free DNase is a recombinant enzyme that is both produced in a non-animal expression system and manufactured without the use of any animal-derived reagents or components at any stage of the production process. These reagents eliminate the risks associated with bovine-sourced enzymes while providing superior purity, defined sequence, and regulatory compliance suitable for advanced biopharmaceutical applications.

Rationale for Animal-Free Production

The shift toward animal-free DNase production is driven by several critical factors. The processes involved in the production and isolation of recombinant DNase I are completely devoid of animal-based components, which eliminates the possibility of introducing animal-derived pathogens into bioprocessing procedures. Using animal origin-free enzymes avoids potential BSE/TSE and mammalian viral risks and regulatory issues associated with bovine and other animal sources. Animal-free enzymes are certified to minimize potential BSE/TSE (prion) and mammalian virus contamination risks.

A critical advantage of recombinant DNase I is the elimination of RNase contamination. Producing DNase I by recombinant means in an organism with much lower levels of endogenous RNase greatly facilitates purification of an enzyme with undetectable levels of RNase. Recombinant DNase I is qualified RNase-free at 320 times typical usage conditions, creating an unsurpassed margin of safety for every application. This is particularly important for RNA workflows, where residual RNase activity can degrade RNA and compromise downstream analyses.